A detailed history of Rbf Capital, LLC transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Rbf Capital, LLC holds 148,451 shares of AVIR stock, worth $510,671. This represents 0.03% of its overall portfolio holdings.

Number of Shares
148,451
Previous 148,451 -0.0%
Holding current value
$510,671
Previous $599,000 18.03%
% of portfolio
0.03%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$3.09 - $4.56 $12,251 - $18,080
-3,965 Reduced 2.6%
148,451 $599,000
Q3 2023

Nov 14, 2023

SELL
$3.0 - $3.79 $18,699 - $23,623
-6,233 Reduced 3.93%
152,416 $457,000
Q2 2023

Aug 14, 2023

SELL
$3.21 - $5.06 $180,658 - $284,776
-56,280 Reduced 26.19%
158,649 $593,000
Q1 2023

May 16, 2023

SELL
$3.0 - $4.97 $159,786 - $264,712
-53,262 Reduced 19.86%
214,929 $720,000
Q4 2022

Feb 14, 2023

BUY
$4.35 - $6.17 $1.17 Million - $1.65 Million
268,191 New
268,191 $1.29 Million

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $286M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Rbf Capital, LLC Portfolio

Follow Rbf Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rbf Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rbf Capital, LLC with notifications on news.